Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥4,425 JPY
Change Today +15.00 / 0.34%
Volume 574.3K
4519 On Other Exchanges
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/18/15 - ¥5,090
52 Week Low
01/7/15 - ¥2,862
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, Perjeta, Kadcyla, and Alecensa; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; co-development agreement with Taisho Pharmaceutical Co., Ltd.; and license agreement and collaboration with Athersys, Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding AG.

7,023 Employees
Last Reported Date: 04/1/15
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd. and Kowa Company, Ltd. Expand the License Agreement to Include US and EU for Chugai's Original Selective SGLT2 Inhibitor

Chugai Pharmaceutical Co., Ltd. and Kowa Company, Ltd. announced that both companies have agreed to expand the license agreement to include US and EU for Chugai's original selective SGLT2 inhibitor, currently marketed by Kowa under the brand name 'DEBERZA tablets 20mg' (generic name: tofogliflozin hydrate) with the indication of type 2 diabetes in Japan. Under this agreement, Kowa will acquire the exclusive rights to develop and market the product, and conduct research, development and marketing activities for the combination drug in the US and EU, while Chugai will be responsible for supplying the drug and active pharmaceutical ingredients (API). Under the terms of this agreement, Chugai will receive an upfront fee, milestone payments and royalty from Kowa.

Chugai Pharmaceutical Co. Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 2015; Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2015

Chugai Pharmaceutical Co. Ltd. expects year end dividend ¥26.00 for the fiscal year ending December 2015. The company reported unaudited consolidated earnings results for the nine months ended September 30, 2015. For the period, the company reported revenues of ¥367,772 million against ¥333,426 million a year ago. Operating profit was ¥67,059 million against ¥59,134 million a year ago. Profit before taxes was ¥67,390 million against ¥59,420 million a year ago. Net income was ¥48,584 million or ¥87.15 diluted per share against ¥40,575 million or ¥72.79 diluted per share a year ago. Net income attributable to Chugai shareholders was ¥47,647 million against ¥39,730 million a year ago. Total cash flows from operating activities were ¥65,921 million against ¥27,453 million a year ago. Purchase of property, plant and equipment was ¥15,470 million against ¥12,083 million a year ago. Purchase of intangible assets was ¥5,868 million against ¥2,446 million a year ago. Free cash flows were a net cash inflow of ¥14.2 billion For the year ending December 31, 2015, the company expects revenues of ¥486,500 million, core operating profit of ¥85,000 million and core earnings per share of ¥104.42.

Chugai Pharmaceutical Co., Ltd. to Construct New Plant for Manufacturing Antibody Active Pharmaceutical Ingredients

Chugai Pharmaceutical Co. Ltd. announced the decision to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) capable of high-mix low-volume production for late-stage investigational drugs and initial commercial products at the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing Co. Ltd. Chugai has been continuously conducting new drug development aiming for the high level of quality and speed under the strategic alliance with F. Hoffman-La Roche Ltd. In 2012, it established a research laboratory in Singapore, Chugai Pharmabody Research Pte. Ltd. (CPR), focusing on drug discovery research applying its proprietary antibody engineering technologies. Furthermore, Chugai has adopted various measures to maximize the value of drug candidates arising from its research, such as the amendments to the out-licensing agreement of Chugai products to Roche and the establishment of the Translational Clinical Research Division. The productivity to continuously generate innovative drug candidates is expected to increase as a consequence of these initiatives. Correspondingly, Chugai has also reinforced its production capacity for investigational drugs, and a capital investment of JPY 2.9 billion is ongoing from 2013 to 2015 at Ukima Plant to double its production capacity of antibody drugs in order to accommodate the simultaneous development of drug candidates. Since this reinforcement of production facility has been working successfully, Chugai made a decision to invest for a new production plant manufacturing antibody API to enlarge the capability to meet the demand of initial commercial products in the future. This new plant will enable seamless high-mix low-volume production of antibody API for investigational drugs in late-stage clinical studies to initial commercial products. Chugai is aiming to possess global top-class competitiveness by minimizing the time required from the development to launch of a new drug by handling the simultaneous development of multiple products. With this capital investment, six 6,000 L bioreactor tanks will be newly installed. Combined with the existing two 2,500 L tanks and four 2,000 L tanks, the Ukima Plant will have a total capacity of 49,000 L bioreactor tanks, with a consistent system from process development to production of antibody API of investigational drugs in late-stage clinical studies and initial commercial products at one site. Construction is scheduled to commence in January 2016, and the demolition of old facilities is currently underway. The total amount for this capital investment is JPY 37.2 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥4,425.00 JPY +15.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.00 USD -0.29
Eli Lilly & Co $83.65 USD -0.09
Merck KGaA €96.27 EUR +0.02
Sanofi €83.83 EUR -0.18
Teva Pharmaceutical Industries Ltd $63.47 USD +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 40.1x
Price/Sales 4.8x
Price/Book 3.8x
Price/Cash Flow 40.1x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at